The FDA approved as companion diagnostic test the Therascreen®, PIK3CA RGQ PCR Kit for the detection of the PIK3CA mutations with the liquid biopsy in breast cancer patients with this setting, based on the results of SOLAR-1 trial [249]. This evidence concerns the gene PIK3CA and breast carcinoma.